New heart lead could simplify pacing for heart failure patients
NCT ID NCT07406737
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test a new type of defibrillator lead designed to pace a specific area of the heart's electrical system. Researchers want to see if these leads can effectively treat heart failure while possibly reducing the number of leads needed. The study plans to enroll 200 people who need cardiac resynchronization therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lumenless defibrillation lead for left bundle branch area pacing
- What this could lead to
- If successful, this could simplify heart failure device therapy by using fewer leads, potentially reducing complications and improving pacing effectiveness.
- What could go wrong
- This is an early registry, not a randomized trial. The new leads may not work as well as standard ones, and long-term safety is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC RESYNCHRONIZATION THERAPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Caen University Hospital
Caen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simpler heart device be just as effective?
- Smarter heart pacing could cut hospital stays for heart failure patients
- Can we predict who benefits from a heart device? new study aims to find out
- New pacemaker technique could rival standard for heart failure
- Pacemaker type may influence arm strength and balance, study finds
- New pacemaker technique aims to prevent heart damage